Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today

Today, two key catalysts are taking PMCB stock higher, as investors seem to like the positioning of biotech PharmaCyte.

What Is the Big SPRT Stock Catalyst Coming on Sept. 10?

Today, investors in SPRT stock are seeing another green day, as investors become increasingly bullish on the company's upcoming merger.

PLTR Stock Price Predictions: How High Can Red-Hot Palantir Go?

Here's where the experts think PLTR stock could be headed from here, for those considering this stock after yesterday's solid earnings.

GRNV Stock: Why Little-Known GreenVision Is Rocketing Ahead of the Helbiz SPAC Merger

Today, investors in GRNV stock are seeing absolutely massive gains, as investors flock to this stock on heavy volume in early trading.

Dear SESN Stock Fans, Mark Your Calendars for August 18

Today, a key upcoming decision on Aug. 18 is driving investors to consider SESN stock today, a major player in the bladder cancer space.